Risk of cataracts with ivacaftor (Kalydeco) reported in animal studies

Source: Reuters Health News
Area: News
The FDA has highlighted on its website the findings from a study in juvenile rats of the risk of developing cataracts with cystic fibrosis drug ivacaftor (Kalydeco). This information has been added to the label for Kalydeco which was approved in January for patients with cystic fibrosis aged six and older who carry the G551D mutation in the CF transmembrane regulator (CFTR) gene.   According to the study, rats aged 7 to 35 days old developed cataracts after being given a dose of Kalydeco (Read more...)

Full Story →